phenyl acetate has been researched along with mbx-8025 in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 10 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alamoudi, JA; Alnouti, Y; Cable, EE; Chu, H; Duan, Y; Gao, B; Gautam, N; Jiang, L; Lang, S; Schnabl, B; Wang, Y | 1 |
| Bowlus, CL; Choi, YJ; Hirschfield, G; Jones, DE; Kremer, AE; Levy, C; Mayo, MJ; McWherter, CA; Steinberg, A | 1 |
| Aspinall, RJ; Berg, CP; Boudes, P; Bowlus, CL; Choi, YJ; Dörffel, Y; Galambos, MR; Goel, A; Gordon, SC; Harrison, SA; Hirschfield, GM; Jones, DEJ; Kremer, AE; Levy, C; Mayo, MJ; McWherter, CA; Neff, GW; Sheridan, DA; Shiffman, ML; Stanca, CM; Steinberg, A; Swain, MG; Thuluvath, PJ; Vierling, JM | 1 |
| Dhingra, S; Mahadik, JD; May, SB; Tarabishy, Y; Vierling, JM | 1 |
| Mishra, AK; Singh, SP | 1 |
| Cable, EE; Kisseleva, T; Kouno, T; Liu, X; Schnabl, B; Zhao, H | 1 |
| Bates, J; Breckenridge, DG; Hollenback, D; Kusam, S; Mahadevan, S; Marchand, B; Okesli-Armlovich, A; Olson, I; Seung, M; Toteva, M; Trevaskis, JL; Vijayakumar, A; Wang, T | 1 |
| Bowlus, CL; Hirschfield, GM; Levy, C | 1 |
| Dyson, JK; Jones, DEJ; Wetten, A | 1 |
| Andreone, P; Aspinall, RJ; Boudes, PF; Bowlus, CL; Choi, YJ; Corpechot, C; Dalekos, GN; Drenth, JPH; Fassio, E; Forman, L; Gonzalez-Huezo, MS; Gordon, SC; Gulamhusein, A; Heneghan, MA; Hinrichsen, H; Hirschfield, GM; Invernizzi, P; Janczewska, E; Jeong, SH; Jones, DEJ; Kowdley, KV; Kremer, AE; Ladrón de Guevara, AL; Lawitz, EJ; Leggett, BA; Levy, C; Mayo, MJ; McWherter, CA; Nevens, F; Pratt, DS; Raikhelson, K; Ryder, SD; Shiffman, ML; Steinberg, A; Swain, MG; Trivedi, PJ; Vargas, V; Vierling, JM; Zigmond, E; Zuckerman, E | 1 |
2 trial(s) available for phenyl acetate and mbx-8025
| Article | Year |
|---|---|
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
Topics: Acetates; Adult; Alkaline Phosphatase; Disease Progression; Humans; Liver Cirrhosis, Biliary; Pruritus; Ursodeoxycholic Acid | 2022 |
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Topics: Acetates; Alkaline Phosphatase; Cholagogues and Choleretics; Humans; Liver Cirrhosis, Biliary; Pruritus; Ursodeoxycholic Acid | 2023 |
8 other study(ies) available for phenyl acetate and mbx-8025
| Article | Year |
|---|---|
The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice.
Topics: Acetates; Animals; Bile Acids and Salts; Ethanol; Female; Gastrointestinal Microbiome; Homeostasis; Liver Diseases, Alcoholic; Mice; Mice, Inbred C57BL; PPAR delta | 2021 |
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.
Topics: Acetates; Bile Acids and Salts; Fatigue; Humans; Liver Cirrhosis, Biliary; Pruritus; Quality of Life; Sleep; Treatment Outcome | 2022 |
Prevalence and clinical significance of portal inflammation, portal plasma cells, interface hepatitis and biliary injury in liver biopsies from patients with non-alcoholic steatohepatitis.
Topics: Acetates; Adolescent; Adult; Aged; Alkaline Phosphatase; Biopsy; Female; Fibrosis; Hepatitis; Humans; Inflammation; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Plasma Cells; PPAR delta; Prevalence; Young Adult | 2022 |
Seladelpar in patients with primary biliary cholangitis: Need for a closer look!
Topics: Acetates; Cholagogues and Choleretics; Cholangitis; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid | 2022 |
Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway.
Topics: Acetates; Animals; Bile Acids and Salts; Cholesterol 7-alpha-Hydroxylase; Fibroblast Growth Factors; Hepatocytes; Humans; Mice; PPAR delta; Signal Transduction | 2022 |
Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
Topics: Acetates; Acetyl-CoA Carboxylase; Animals; Fenofibrate; Humans; Hypertriglyceridemia; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; PPAR alpha; Rats; Triglycerides | 2022 |
Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!"
Topics: Acetates; Cholangitis; Humans; Liver Cirrhosis, Biliary | 2022 |
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC).
Topics: Acetates; Clinical Trials as Topic; Drugs, Investigational; Humans; Liver Cirrhosis, Biliary | 2022 |